 |
|
|||||
Dr. Tahseen Mozaffar is a Professor of Neurology, Professor of Orthopaedic Surgery, and Director of the UC Irvine Neuromuscular Program. He is a practicing clinician-scientist, a neurologist, and directs the UC Irvine-MDA ALS and Neuromuscular Diseases Center. He is part of a national group of scientists who have identified the active genes in sporadic amyotrophic lateral sclerosis (ALS), a discovery that provides expanded opportunities for developing therapies to treat this chronic, incurable disease As a nationally recognized expert in his field, Mozaffar serves as a principal investigator and co-investigator in clinical trials of novel therapeutic drugs for ALS, as well as other neuromuscular conditions. His research interests focus on the pathophysiology of neuromuscular disorders, encompassing nerve dysfunction and the molecular and cellular aspects of muscle atrophy. Among Dr. Mozaffar's publications are dozens of original peer-reviewed research articles, book chapters and invited reviews. In recognition of his academic achievements he was elected a member of the American Neurological Association; in the same year he was also elected a fellow of the American Academy of Neurology. He is currently president of the Orange County Neurological Society; he sits on numerous committees of professional associations and medical research foundations. Responding to the strong interest in neuromuscular research within the medical community, Dr. Mozaffar is a frequent lecturer, guest speaker and presenter at medical grand rounds, professional meetings and research conferences. He also supports public awareness of advances in neuromuscular research by speaking at gatherings of patients and caregivers. Dr. Mozaffar is a highly regarded teacher, and has received many awards for his contributions to the education of neurologists, both at UC Irvine and other institutions. He also acts as an advisor to medical organizations developing novel diagnostic technologies and promising treatments for neuromuscular diseases. California Stem Cell is currently collaborating with Dr. Mozaffar on a clinical trial designed for the treatment of ALS patients with California Stem Cell's MotorGraft™ therapy. Dr. Mozaffar will be the Principal Investigator (PI) for that ALS study. |
StemBlast Media® Specialized, proprietary, serum-free media designed for the propagation of hESCs and hiPSCs. Live Cells on Demand! California Stem Cell is now shipping high purity populations of fully characterized hESC-derived human cells in an ideal format for drug screening and predictive toxicology. |
|||||
